| 產(chǎn)品編號(hào) | bsm-60935R |
| 英文名稱 | KEAP1 Recombinant Rabbit mAb |
| 中文名稱 | 胞質(zhì)接頭蛋白Keap1重組兔抗體 |
| 別 名 | Cytosolic inhibitor of Nrf2; INrf 2; INrf2; Keap 1; KEAP1; KEAP1_HUMAN; Kelch like ECH associated protein 1; Kelch like protein 19; Kelch-like ECH-associated protein 1; Kelch-like protein 19; KIAA0132; KLHL 19; KLHL19; MGC10630; MGC1114; MGC20887; MGC4407 |
| 抗體來源 | Rabbit |
| 克隆類型 | Recombinant |
| 克 隆 號(hào) | 7B13 |
| 交叉反應(yīng) | Human |
| 產(chǎn)品應(yīng)用 | WB=1:500-2000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 69 kDa |
| 檢測(cè)分子量 | |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human KEAP1 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
This gene encodes a protein containing KELCH-1 like domains, as well as a BTB/POZ domain. Kelch-like ECH-associated protein 1 interacts with NF-E2-related factor 2 in a redox-sensitive manner and the dissociation of the proteins in the cytoplasm is followed by transportation of NF-E2-related factor 2 to the nucleus. This interaction results in the expression of the catalytic subunit of gamma-glutamylcysteine synthetase. Two alternatively spliced transcript variants encoding the same isoform have been found for this gene. [provided by RefSeq, Jul 2008]. SWISS: Q14145 Gene ID: 9817 Keap1是細(xì)胞抗氧化反應(yīng)的重要調(diào)節(jié)蛋白，Keap1與Nrf2/ARE構(gòu)成的信號(hào)通路在抗腫瘤、抗應(yīng)激、調(diào)節(jié)GSH合成、抗凋亡、抗炎反應(yīng)、神經(jīng)保護(hù)等方面發(fā)揮著廣泛的細(xì)胞保護(hù)作用。 |
| 產(chǎn)品圖片 |
25 ug total protein per lane of various lysates (see on figure) probed with KEAP1 monoclonal antibody, unconjugated (bsm-60935R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.
|
